Profile data is unavailable for this security.
About the company
Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs. Tibulizumab (ZB-106) is an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of TALTZ (ixekizumab) and tabalumab that neutralizes IL-17A and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain (IL-7R) alpha. Torudokimab (ZB-880) is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.
- Revenue in USD (TTM)0.00
- Net income in USD-42.62m
- Incorporated2021
- Employees14.00
- LocationZura Bio Ltd4225 Executive Square, Suite - 600SAN DIEGO 92037United StatesUSA
- Phone+1 (858) 247-0520
- Websitehttps://zurabio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiaMedica Therapeutics Inc | 0.00 | -21.71m | 178.69m | 18.00 | -- | 3.73 | -- | -- | -0.5527 | -0.5527 | 0.00 | 1.12 | 0.00 | -- | -- | 0.00 | -39.23 | -45.38 | -41.66 | -48.24 | -- | -- | -- | -- | -- | -- | 0.0055 | -- | -- | -- | -41.72 | -- | -13.65 | -- |
| Caribou Biosciences Inc | 11.48m | -148.12m | 179.29m | 158.00 | -- | 0.6376 | -- | 15.62 | -1.65 | -1.65 | 0.128 | 3.11 | 0.0286 | -- | 5.08 | 72,626.59 | -36.94 | -- | -39.76 | -- | -- | -- | -1,290.81 | -- | -- | -1,321.46 | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
| Fulcrum Therapeutics Inc | 80.87m | -17.91m | 185.33m | 76.00 | -- | 0.6226 | -- | 2.29 | -0.3098 | -0.3098 | 1.29 | 4.77 | 0.2899 | -- | 23.41 | 1,064,092.00 | -6.42 | -50.55 | -6.77 | -55.91 | -- | -- | -22.15 | -1,189.10 | -- | -- | 0.00 | -- | -55.77 | -- | 11.41 | -- | -43.70 | -- |
| Nektar Therapeutics | 93.14m | -168.30m | 186.30m | 137.00 | -- | 3.81 | -- | 2.00 | -0.8371 | -0.8371 | 0.4634 | 0.265 | 0.2483 | 3.96 | 84.52 | 679,832.10 | -44.87 | -31.02 | -53.39 | -34.63 | 67.80 | 78.04 | -180.70 | -372.21 | 4.24 | -15.53 | 0.00 | -- | -2.10 | -40.35 | 25.03 | -- | -42.89 | -- |
| ADC Therapeutics SA | 70.72m | -212.15m | 187.58m | 273.00 | -- | -- | -- | 2.65 | -2.40 | -2.40 | 0.7742 | -1.78 | 0.1733 | 0.2987 | 3.13 | 259,036.60 | -51.13 | -48.41 | -62.27 | -55.63 | 91.81 | -- | -295.00 | -308.62 | 4.68 | -3.92 | 1.65 | -- | -66.86 | 127.56 | -52.78 | -- | 5.42 | -- |
| Compass Therapeutics Inc. | 850.00k | -47.76m | 189.87m | 32.00 | -- | 1.37 | -- | 223.38 | -0.3553 | -0.3553 | 0.0063 | 1.01 | 0.0053 | -- | -- | 26,562.50 | -29.93 | -41.75 | -31.25 | -46.41 | -- | -- | -5,618.71 | -- | -- | -- | 0.00 | -- | -- | -- | -8.33 | -- | -56.91 | -- |
| Zura Bio Ltd | 0.00 | -42.62m | 191.31m | 14.00 | -- | 1.25 | -- | -- | -0.5807 | -0.5807 | 0.00 | 2.34 | 0.00 | -- | -- | 0.00 | -32.18 | -- | -43.31 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2,050.99 | -- | -- | -- |
| Editas Medicine Inc | 61.76m | -210.57m | 195.64m | 265.00 | -- | 1.11 | -- | 3.17 | -2.56 | -2.56 | 0.752 | 2.13 | 0.1484 | -- | 48.48 | 233,049.10 | -50.61 | -29.85 | -60.06 | -33.19 | -- | -- | -340.96 | -347.71 | -- | -- | 0.00 | -- | 296.32 | 19.59 | 30.49 | -- | -0.1477 | -- |
| Enanta Pharmaceuticals Inc | 71.96m | -115.33m | 197.27m | 145.00 | -- | 1.32 | -- | 2.74 | -5.46 | -5.46 | 3.41 | 7.03 | 0.161 | -- | 5.32 | 496,275.90 | -25.80 | -14.56 | -30.05 | -15.62 | -- | -- | -160.27 | -54.96 | -- | -- | 0.0095 | -- | -8.07 | -17.45 | -9.91 | -- | 24.89 | -- |
| Acrivon Therapeutics Inc | 0.00 | -76.98m | 199.46m | 58.00 | -- | 1.02 | -- | -- | -2.70 | -2.70 | 0.00 | 6.32 | 0.00 | -- | -- | 0.00 | -42.09 | -- | -45.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.76 | -- | -- | -- |
| Climb Bio Inc | 0.00 | -69.12m | 201.18m | 9.00 | -- | 0.9218 | -- | -- | -2.13 | -2.13 | 0.00 | 3.25 | 0.00 | -- | -- | 0.00 | -41.28 | -- | -42.07 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
| MacroGenics Inc | 141.33m | -97.62m | 201.47m | 339.00 | -- | 1.68 | -- | 1.43 | -1.57 | -1.57 | 2.26 | 1.91 | 0.4676 | 3.24 | 8.30 | 416,899.70 | -32.30 | -37.76 | -39.53 | -45.53 | 95.07 | -- | -69.07 | -133.96 | 3.69 | -93.94 | 0.00 | -- | -61.33 | -0.4606 | 92.44 | -- | -41.13 | -- |
| XBiotech Inc | 0.00 | -32.66m | 201.67m | 92.00 | -- | 1.05 | -- | -- | -1.07 | -1.07 | 0.00 | 6.30 | 0.00 | -- | -- | 0.00 | -14.86 | 31.88 | -15.62 | 33.27 | -- | -- | -- | 877.30 | -- | -- | 0.0495 | 0.00 | -100.00 | -- | 25.36 | -- | 24.30 | -- |
| Perspective Therapeutics Inc | -3.68m | -53.78m | 202.28m | 116.00 | -- | 0.6171 | -- | -- | -1.24 | -1.59 | -0.069 | 4.86 | -0.0147 | -- | -- | -31,741.38 | -21.44 | -- | -23.11 | -- | -- | -- | -- | -- | -- | -- | 0.0051 | -- | -- | -- | -- | -- | -- | -- |
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -38.70m | 203.76m | 19.00 | -- | 1.35 | -- | -- | -4.69 | -4.69 | 0.00 | 12.36 | 0.00 | -- | -- | 0.00 | -38.61 | -86.84 | -49.21 | -130.46 | -- | -- | -- | -769.76 | -- | -- | 0.00 | -- | -- | -- | -5.33 | -- | -- | -- |
| Lexeo Therapeutics Inc | 0.00 | -86.60m | 204.98m | 58.00 | -- | 1.47 | -- | -- | -2.89 | -2.89 | 0.00 | 4.21 | 0.00 | -- | -- | 0.00 | -75.77 | -- | -96.90 | -- | -- | -- | -- | -- | -- | -- | 0.0107 | -- | -100.00 | -- | -12.01 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Zura Bio Ltd's reporting currency: US Dollar USD
43.95%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Suvretta Capital Management LLCas of 30 Sep 2024 | 4.86m | 7.62% |
| Adar1 Capital Management LLCas of 30 Sep 2024 | 3.77m | 5.91% |
| Deep Track Capital LPas of 30 Sep 2024 | 3.28m | 5.15% |
| Great Point Partners LLCas of 30 Sep 2024 | 3.26m | 5.12% |
| RA Capital Management LPas of 30 Sep 2024 | 3.22m | 5.05% |
| Braidwell LPas of 30 Sep 2024 | 2.47m | 3.88% |
| Point72 Asset Management LPas of 30 Sep 2024 | 2.41m | 3.78% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 2.20m | 3.45% |
| Armistice Capital LLCas of 30 Sep 2024 | 1.50m | 2.35% |
| StemPoint Capital LPas of 30 Sep 2024 | 1.04m | 1.64% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
